SUMMARY: Nontuberculous mycobacteria (NTM) are associated with a number of clinical diseases and only a few antitubercular agents are active against them. Oxazolidinones comprise a novel class of antimicrobials that inhibit bacterial protein synthesis at the ribosome. Linezolid, the first oxazolidinone antibacterial agent approved for clinical use, has excellent activity against some NTM but is ineffective against others. Sy142 and sy144 are novel oxazolidinones with demonstrated activties against Mycobacterium tuberculosis and Staphylococcus aureus. In this work, we compared the susceptibilities of key NTM species to linezolid, sy142, and sy144. The organisms included 21 isolates of Mycobacterium abscessus, 31 of Mycobacterium avium, 11 of Mycobacterium chelonae, 24 of Mycobacterium fortuitum, 26 of Mycobacterium kansasii, and 17 of Mycobacterium intracellulare. For M. kansasii and M. fortuitum, linezolid showed excellent antimicrobial activity, and an equal MIC range was found in sy142 and sy144. For the species that linezolid was less active against, sy142 and sy144 showed greater antimicrobial activities or exhibited equal compared to linezolid. Particularly, for M. avium and M. intracellulare, the in vitro antimicrobial activity of sy142 was 4-fold higher than that of linezolid. These results demonstrate the potential of these compounds to treat NTM infections.
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Nontuberculous mycobacteria (NTM) are associated with a number of clinical diseases, including lymphadenitis, skin abscesses, disseminated infections, and pulmonary infections. Until recently, the treatment of most NTM diseases has been difficult. The most commonly isolated species include the Mycobacterium avium complex, Mycobacterium kansasii, Mycobacterium marinum, Mycobacterium chelonae, Mycobacterium abscessus, and Mycobacterium fortuitum. Most of these species are resistant to conventional antitubercular antimicrobials, and only a few agents are active against them (1) (2) (3) .
Oxazolidinones comprise a novel class of antimicrobials as inhibitors of bacterial protein synthesis. The mechanism of action is that they prevent the formation of the 70S ribosomal initiation complex by binding to a site on the 50S ribosomal subunit near its interface with the 30S subunit. Linezolid was the first oxazolidinone antibacterial agent that was approved for clinical use, it has a broad spectrum activity against gram-positive bacteria and is currently approved for use in the treatment of complicated skin structure infections and hospitalacquired pneumonia. It has also shown good activity against Mycobacterium tuberculosis (MTB), regardless of MTB drug resistant patterns (4) . However, the efficacy of linezolid against NTM varies among different species (5,6). In our previous work, we identified a series of novel 4-substituted piperazinyl phenyl oxazolidinone analogues; among them the antimicrobial activities of sy142 and sy144 against MTB and Staphylococcus aureus are comparable to those of linezolid (7, 8) . To date, the efficacy of these compounds against NTM has rarely been reported. Using clinical NTM strains isolated from the 309th Hospital of Chinese People's Liberation Army (PLA 309th Hospital), we performed a comparative study of the susceptibilities of key NTM species to the identified oxazolidinone analogues in vitro.
Clinical isolates were identified at the species level using a commercial DNA-RNA probe (M. avium complex and M. kansasii) or by PCR restriction fragment length polymorphism analysis of a 441-bp sequence (Telenti fragment) of the hsp65 gene as previously described (9) . The reference isolates were provided by the Beijing Institute for Tuberculosis Control. The isolates tested herein were M. abscessus (21 isolates), M. avium complex (31 isolates), M. chelonae (11 isolates), M. fortuitum (24 isolates), M. kansasii (26 isolates), and M. intracellulare (17 isolates).
Linezolid was obtained from Promega (Madison, WI, USA; PS1074); the synthesis and structure of sy142 and sy144 were described previously (7) . Drug susceptibility testing of conventional drugs was performed using the proportion method according to the WHO Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update <http://whqlibdoc.who.int/ publications>. We tested 4 first-line anti-tuberculosis drugs (rifampin [ Efficacies of Oxazolidinones against Nontuberculous Mycobacteria azolidinone analogues were determined using serial 2-fold broth microdilutions in cation-adjusted MuellerHinton broth (10) after 7 days of incubation at 359 C. The end point was complete (100z) inhibition of visible growth. As seen in Table 1 , EMB was the most useful first line agent against NTM, with an overall resistance rate among the tested isolates of 60z. Drug resistance rates were 100z for INH, 90z for RFP, and 94.6z for SM. In the second-line drugs, the highest drug resistance rate was to PAS (91.5z), followed by ofloxacin (69.2z), while the lowest resistant rates were for amikacin and capreomycin. Linezolid showed excellent activity against M. kansasii, and M. fortuitum, with MIC ranges of 0.5-1 mg/L and 0.5-8 mg/L, respectively, which was in accordance with previous reports (5, 6) . Similarly, the in vitro activities of sy142 and sy144 against these two species were comparable to those of linezolid. The MIC ranges of sy142 for 26 isolates of M. kansasii was 0.25-1 mg/L, and that of sy144 was 0.5-1 mg/L. For 24 isolates of M. fortuitum, the MICs of sy142 and sy144 were slightly higher than that of linezolid (Table 2) . Linezolid was less active in vitro against isolates of M. avium, M. abscessus, M. intracellulare, and M. chelonae. For isolates of M. avium and M. intracellulare, the MIC range of linezolid was 8-64 mg/L. The in vitro activities of sy142 and sy144 against these isolates were greater than that of linezolid; particularly, sy142 was 4-fold more active than linezolid. The MICs of linezolid against M. abscessus isolates were quite high (MIC range 16-64 mg/L), and the same results were also found for sy142 and sy144. The MIC range of linezolid against 11 isolates of M. chelonae was 2-16 mg/L, and sy142 showed slightly higher activities whereas sy144 exhibited equal efficacy compared to linezolid (Table 2) .
Common antimicrobial therapy for NTM infections includes the use of aminoglycosides, macrolides, fluoroquinolones, and antituberculosis agents such as RFP and EMB, and their use depends on the species identified. However, outbreaks of highly drug resistant NTM infections to general antibiotics seriously threaten the control of the related pulmonary diseases. In China, because antibiotics are widely overused to treat infections, it is believed that the existence of drug-resistance patterns is highly likely. According to a report by Jing et al., there was a 100z resistance rate for INH among all NTM strains isolated in China, followed by the resistance rates to SM (98z), RFP (78z), and EMB (51z) (2). Wang et al. have reported similar results and found that the M. avium complex and M. abscessus, which were the most prevalent species, were resistant to test drugs in ＞90z of the cases, thus highlighting the difficulties associated with the treatment of certain NTM infections (11) . Here, we present the results of drug-resistance patterns of bacterial isolates from the PLA 309th Hospital and show significant rates of NTM resistance to first-line and second-line anti-tuberculosis drugs. Together with the other data reported in China, we can conclude that new options for antibiotic therapy are urgently needed.
There is marked geographic variability in the etiology of NTM lung disease. Wang et al. reported that the most commonly encountered species of NTM in Shanghai were M. chelonae, followed by M. fortuitum, M. kansasii, the M. avium-intracellulare complex, and Mycobacterium terrae (11) . In the Beijing chest hospital, the common species were M. intracellulare, M. abscessus, M. fortuitum, Mycobacterium gordonae, M. kansasii, M. avium, and Mycobacterium parascrofulaceum (3). Therefore, the most common NTM isolates were selected to test the antimicrobial activities of the drugs herein. For linezolid, the peak physiological concentration obtained after oral adminis-tration of 600 mg twice a day is 21.2 ± 5.8 mg/L, with a half-life of 5.4 h; therefore, it was recommended that 8 mg/L be set as the breakpoint.
In the present study, linezolid demonstrated similar activities against most mycobacterial isolates in agreement with previous reports (5, 6) . However, the M. avium complex and M. abscessus required 32 mg/L to inhibit 90z of the isolates tested, indicating that treatment with linezolid against these two species is difficult. It is promising that sy142 exhibited better efficacy against the M. avium complex with an MIC 90 of 16 mg/L, which was approximately 2-to 4-fold lower than that of linezolid, suggesting that it could provide a backbone for the development of new oxazolidinones as anti-NTM drug candidates.
